Yale Cancer Center (YCC) scientists will be presenting more than 45 research studies at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). The annual meeting takes place May 31-June 4 in Chicago and brings together more than 32,000 oncology professionals from around the world.
Some of the research highlights to be presented by YCC scientists at the annual meeting include:
- Amy Davidoff, Ph.D. - An analysis of electronic health records looking at the relationship between the Affordable Care Act-related Medicaid expansion and racial disparities in receiving timely cancer treatment.
- Joseph Paul Eder, M.D. - Five-year survival data from the KEYNOTE-001 trial looking at the safety and effectiveness of pembrolizumab in metastatic non-small cell lung cancer.
- Daniel Petrylak, M.D. - A single arm, phase II clinical trial exploring enfortumab vedotin (EV) monotherapy in patients with locally advanced or metastatic forms of urothelial cancer or bladder cancer.
Some of the Educational Sessions and Clinical Science Symposiums headed by YCC scientists at the annual meeting include:
- Barbara Burtness, M.D. – Point/Counterpoint: Do we de-intensify treatment for HPV-positive Oropharynx Cancer now and how?
- Katerina A. Politi, Ph.D. – How can we overcome TKI Resistance in EGFR-mutant NSCLC
- Roy Herbst, M.D., Ph.D. – Meet the Professor: The future of Immunotherapy in non-small cell lung cancer
- Mario Sznol, M.D. – Recognizing, Understanding and Overcoming Toxicities from Immune Checkpoint Inhibitors
- Gloria Huang, M.D. – Are we hitting the bull’s-eye with targeted therapy?
For more information about Yale Cancer Center participation at ASCO visit our website at: https://www.yalecancercenter.org/Images/ASCO%20Meeting%202019_tcm471-356592.pdf